- Preclinical and Phase 1 Data Scheduled for Presentation at 47th ICAAC on
September 18-19, 2007 -
CARLSBAD, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC) announced today that it has successfully completed Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers.
The data from these Phase 1 clinical trials, together with select preclinical data, will be discussed in four poster presentations at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which is being held September 17-20 in Chicago, Illinois. Abstracts can be accessed on the official ICAAC web site at http://www.icaac.org. The poster titles and presentation details are as follows:
-- "The Discovery of RDEA806: A Potent New HIV NNRTI in Phase 1 Clinical
Trials" will be presented during Poster Session 101 (HIV: New Drugs),
Poster Board #299, Abstract #3285, on Tuesday, September 18,
12:15-1:15 PM in Hall D.
-- "RDEA806: A Potent NNRTI with Broad Activity Against Resistant Strains
of HIV-1 and a High Genetic Barrier to Resistance" will be presented
during Poster Session 101 (HIV: New Drugs), Poster Board #300, Abstract
#1662, on Tuesday, September 18, 12:15-1:15 PM in Hall D.
-- "Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806,
a Novel HIV NNRTI, in Healthy Volunteers" will be presented during
Poster Session 160 (Antiviral Agents), Poster Board #23, Abstract
#1609, on Wednesday, September 19, 11:15 AM-12:15 PM in Hall D.
-- "RDEA806, a Potent Non-Nucleoside Reverse Transcriptase Inhibitor with
Less Potential for Drug-Drug Interactions" will be presented during
|SOURCE Ardea Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved